DataMeds AI, Inc.: regains compliance with Nasdaq Listing Rule 5550(b)(1)

What happened

• The filing says DataMeds AI, Inc. announced on Oct 20, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(b)(1). The press release was attached to the Form 8-K as Exhibit 99.1.
• The filing also says the Company received a deficiency letter from the Nasdaq Listing Qualifications Department on Apr 13, 2026 based on the Company’s reported stockholders’ equity of $(12,447,801) in its Annual Report on Form 10-K for the fiscal year ended Dec 31, 2025, and that as of the date of that letter the Company did not meet the $2,500,000 minimum stockholders’ equity requirement or the alternative standards. The filing says the Company received written notice from the Nasdaq Staff on Oct 19, 2026 informing the Company that it has regained compliance.

Key details

• Deficiency letter received from Nasdaq on Apr 13, 2026.
• Stockholders’ equity reported as $(12,447,801) in the Form 10-K for the year ended Dec 31, 2025.
• Nasdaq minimum stockholders’ equity requirement: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)).
• Nasdaq Staff notice of regained compliance dated Oct 19, 2026; press release issued Oct 20, 2026 and attached as Exhibit 99.1.

Why it may matter

• Item 7.01 (Regulation FD disclosure) was reported for the press release announcing regained compliance. Item 8.01 (Other events) was reported for the earlier Nasdaq deficiency letter and the later Staff notice of compliance.
• A filing does not show why the insider traded or why the company acted.